Updates are available Correction dated 2025-07-03
Click to view Correction: https://doi.org/10.1186/s12967-025-06781-z
-
Authors
Popa-Navarro, Xitlally
Avilés-Salas, Alejandro
Hernández-Pedro, Norma
Orozco-Morales, Mario
Caballé-Pérez, Enrique
Castillo-Ruiz, Cesar
Lucio-Lozada, José
Barrios-Bernal, Pedro
Hernandez-Martinez, Juan-Manuel
Arrieta, Oscar https://orcid.org/0000-0002-1164-3779
- License Information
-
More Information
Article History
Received: 25 March 2024
Accepted: 3 July 2024
First Online: 12 September 2024
Change Date: 28 June 2025
Change Type: Update
Change Details: Authorship has been corrected
Change Date: 3 July 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12967-025-06781-z
Declarations
:
: This study was conducted in compliance with ethical standards stablished by the Declaration of Helsinki, and it was approved by the Ethics and Scientific Board Review Committee of the Instituto Nacional de Cancerología [(018/063(ICI) (CEI/1303/18)]..
: Written informed consent was not applicable.
: Oscar Arrieta reports receiving personal fees from Pfizer, Lilly, Merck, and Bristol-Myers Squibb and grants and personal fees from AstraZeneca, Boehringer Ingelheim, and Roche, outside of this submitted work. The rest of authors declare no affiliations with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript.
